Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$--
EBITDA
$--
Net Profit
$--
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
RVL Pharmaceuticals plc (RVLPQ)
| -99.00 | -- | -- | -99.00 | -- | -- | -- |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
2024
|
|
|---|---|
|
RVL Pharmaceuticals plc (RVLPQ)
| -96.67 |
|
BSE Sensex
| 8.10 |
|
BSE Sensex
| 8.10 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas... in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. Address: 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807 Read more
Chairman, President, CEO & Principal Financial Officer
Mr. Brian A. Markison
Chairman, President, CEO & Principal Financial Officer
Mr. Brian A. Markison
Headquarters
Bridgewater, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of RVL Pharmaceuticals plc (RVLPQ) is $0.00 (NASDAQ) as of 16-Apr-2025 13:22 EDT. RVL Pharmaceuticals plc (RVLPQ) has given a return of -99% in the last 1 years.
RVL Pharmaceuticals plc (RVLPQ) has a market capitalisation of $ 0 Mln as on 17-Apr-2025. As per Value Research classification, it is a company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the RVL Pharmaceuticals plc (RVLPQ) and enter the required number of quantities and click on buy to purchase the shares of RVL Pharmaceuticals plc (RVLPQ).
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. Address: 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807
The CEO & director of Mr. Brian A. Markison. is RVL Pharmaceuticals plc (RVLPQ), and CFO & Sr. VP is Mr. Brian A. Markison.
There is no promoter pledging in RVL Pharmaceuticals plc (RVLPQ).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| RVL Pharmaceuticals plc (RVLPQ) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of RVL Pharmaceuticals plc (RVLPQ) was $0 Mln.
$--
(
